

**AMENDMENTS IN THE CLAIMS**

No amendment has been made by this Response.

1           1. (Previously Presented) A method for controlling chronic inflammation in an  
2 individual having Metabolic Syndrome, comprising:

3           administering to said individual an effective dosage of a pharmaceutical composition  
4 selected from the group consisting of YG-Product, YGG-Product, Purified Leukocyte Dialysate  
5 Subfraction, and a combination thereof.

1           2. (Original) The method of claim 1, wherein the chronic inflammation is evidenced by  
2 at least one of elevated C-Reactive Protein and elevated serum fibrinogen.

1           3. (Previously Presented) The method of claim 1, wherein the chronic inflammation is  
2 evidenced by at least one of elevated platelet count and elevated platelet activity.

1           4. (Original) The method of claim 1, wherein the individual has at least one condition  
2 selected from the group consisting of hypertension, hypercholesterolemia, hypertriglyceridemia,  
3 and obesity.

1           5. (Canceled)

1           6. (Previously Presented) The method of claim 1, wherein the individual has at least one  
2 condition selected from the group consisting of obesity, insulin resistance, hypertension,

dyslipidemia, impaired glucose tolerance, accompanied by increased acute phase proteins including C-Reactive Protein and fibrinogen.

7. (Original) The method of claim 1, wherein said individual has diabetes mellitus, coronary artery disease or cancer.

8. (Withdrawn) A method for controlling elevated blood glucose level in an individual with inflammation-related metabolic disturbances, comprising:

administering to said individual an effective dosage of a composition selected from the group consisting of YG-Product, YGG-Product, Purified Leukocyte Dialysate Subfraction, or a combination thereof.

9. (Withdrawn) The method of claim 8, wherein the individual has at least one component of the Metabolic Syndrome.

10. (Withdrawn) A method for preventing chronic inflammation due to the presence of or potential exposure to a pathogen, environmental particulates, or environmental toxins, said method comprising: administering to said individual an effective dosage of a pharmaceutical composition selected from the group consisting of YG-Product, YGG-Product, Purified Leukocyte Dialysate Subfraction, and a combination thereof.

11. (Withdrawn) A method for mitigating a symptom in a patient, said symptom characteristic of chronic inflammation, said patient presenting said symptom, said method

3 comprising administering to the patient a pharmaceutical preparation containing an effective  
4 dosage amount of YG-Product, YGG-Product, Purified Leukocyte Dialysate Subfraction, or a  
5 combination thereof.

1 12. (Withdrawn) The method of claim 11, wherein said patient has at least one  
2 component of the Metabolic Syndrome.

1 13. (Withdrawn) The method of claim 12, wherein said symptom is at least one selected  
2 from the group consisting of elevated blood pressure, atherogenic dyslipidemia, abdominal  
3 obesity, insulin resistance with or without glucose intolerance, a proinflammatory state, and a  
4 prothrombotic state.

1 14. (Withdrawn) A method for mitigating a symptom in a patient, said symptom  
2 characteristic of an inflammation-related metabolic disturbance, said patient presenting said  
3 symptom, said method comprising administering to the patient a pharmaceutical preparation  
4 containing an effective dosage amount of YG-Product, YGG-Product, Purified Leukocyte  
5 Dialysate Subfraction, or a combination thereof.

1 15. (Withdrawn) The method of claim 14, wherein said patient has at least one  
2 component of the Metabolic Syndrome.

1 16. (Withdrawn) The method of claim 15, wherein said component is at least one  
2 selected from the group consisting of elevated blood pressure, atherogenic dyslipidemia,

3 abdominal obesity, insulin resistance with or without glucose intolerance, a proinflammatory  
4 state, and a prothrombotic state.

1 17. (Withdrawn) A method for deferring the progression of a patient from the Metabolic  
2 Syndrome including Hypertension, to Diabetes Mellitus, Coronary Heart Disease, or Cancer,  
3 said method comprising administering to the patient a pharmaceutical preparation containing an  
4 effective dosage amount of YG-Product, YGG-Product, Purified Leukocyte Dialysate  
5 Subfraction, or a combination thereof.

1 18. (Withdrawn) A method for preventing or mitigating development of inflammation-  
2 related sequelae of exposure of a person to liquids or vapors containing organic solvents or  
3 hydrocarbon fuels, or to environmental toxins capable of provoking chronic inflammation, said  
4 method comprising:

5 (a) administering to the person a pharmaceutical preparation containing an effective  
6 dosage amount of YG-Product, YGG-Product, Purified Leukocyte Dialysate Subfraction, or a  
7 combination thereof;

8 (b) monitoring the person for immune function response, inflammation, and blood  
9 glucose level; and

10 (c) continuing to administer to the patient said pharmaceutical preparation until the  
11 person shows a normal immune function response and normal measures of inflammatory  
12 parameters.